重组人白介素11治疗前期再生障碍性贫血的血小板减少的初步观察

为了评价重组人白介素11治疗前期再生障碍性贫血的血小板减少的疗效，对6例早期再生障碍性贫血患者用重组人白介素11600万单位皮下注射，每日1次，疗程7—14天，并分别于治疗前、治疗后第8天、第15天、第30天、第60天复查外周血血小板，第15天复查骨髓巨核细胞计数。结果表明：显效3例(50％)，良效1例(16．7％)，进步1例(16.7％)，无效1例(16．7％)，总有效率83．3％。全部6例病人骨髓巨核细胞均有不同程度增加，治疗时副作用轻。结论：重组人白介素11治疗前期再生障碍性贫血血小板减少的疗效满意。

Clinical Efficacy of Recombinant Human Interleukin 11 on Thrombocytopenia in Pre-Aplastic Anemia

To evaluate the clinical efficacy of recombinant human Interleukin 11 in the treatment of pre-aplastic anemia, six patients with pre-aplastic anemia were injected with rhIL-11 of 6 million units once a day during 7-14 days. Blood platelet counts were taken on day 8, 15, 30 and 60 after the treatment, and bone marrow examination was performed on day 15 as compared with those before treetment. The results showed that platelet counts in 3 out of 6 patients increased remarkably (50%), one of the six increased moderately (16.7%), another case of the six increased slightly (16.7%), platelet in one out of six did not significantly increase (16.7%), the total efficacy rate is 83.3%, the amount of megakaryocyte in bone marrow of all six patients increased, the side effect of the rhIL-11 treatment was light. In conclusion, the efficacy of recombinant human Interleukin-11 in the treatment of thrombocytopenia patients with pre-aplastic anemia is satistactory. As the number of the cases is too small to conclude, further exploration needs accumnlation of more applications.